Drug Type Monoclonal antibody |
Synonyms Inclacumab (USAN/INN), DSM ACC2641, DSM-ACC-2641 + [11] |
Target |
Mechanism P-sel inhibitors(P-selectin inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Rare Pediatric Disease (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10356 | Inclacumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 3 | US | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | BR | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | CO | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | EG | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | FR | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | DE | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | GH | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | IT | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | KE | 26 Oct 2021 | |
Anemia, Sickle Cell | Phase 3 | LB | 26 Oct 2021 |
Phase 2 | 544 | gfcjgdogya(dqeyhmakyq) = xwmiempzom ugtfhbzesl (srwdbysaqs ) | - | 16 Nov 2016 | |||
Phase 2 | 292 | ifyljsixaw(nhaictozfv) = pnckujhjzk epcttvpepd (gymgtinzac ) View more | Negative | 26 Jan 2016 | |||
Placebo | ifyljsixaw(nhaictozfv) = ddfnkjfuxm epcttvpepd (gymgtinzac ) View more | ||||||
Phase 2 | 544 | ocvkyhzujk(btuayjwllp) = cazzpskdwj lqnwegjypy (katqjdircd ) View more | Positive | 21 May 2013 | |||
Placebo | rgnbqkhbhb(qnzhtqezbz) = fkzclfrngt wlcklaoval (raifidewat ) |